Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the aurora kinase inhibitor VX-680

Cancer Research

Volumn 66, Issue 2, 2006, Pages 1007-1014

  Young, Matthew A ^a,e   Shah, Neil P ^c   Chao, Luke H ^a   Seeliger, Markus ^a   Milanov, Zdravko V ^a   Biggs III, William H ^d   Treiber, Daniel K ^d   Patel, Hitesh K ^d   Zarrinkar, Patrick P ^d   Lockhart, David J ^d   Sawyers, Charles L ^c   Kuriyan, John ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Ambit Biosciences   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; AURORA A KINASE; BCR ABL PROTEIN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; ENZYME INHIBITOR; IMATINIB; ISOLEUCINE; THREONINE;

AMINO ACID SUBSTITUTION; ARTICLE; BLOOD SAMPLING; CHROMOSOME 9; CRYSTAL STRUCTURE; DRUG RESISTANCE; ENZYME ACTIVATION; ENZYME INHIBITOR COMPLEX; ENZYME STRUCTURE; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN;

CATALYTIC DOMAIN; CRYSTALLOGRAPHY; DRUG RESISTANCE, NEOPLASM; ESCHERICHIA COLI; FUSION PROTEINS, BCR-ABL; GENES, ABL; HUMANS; HYDROGEN BONDING; LEUKEMIA, MYELOID, CHRONIC; PHOSPHORYLATION; PIPERAZINES; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; THIAZOLES;

EID: 31644438945     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2788     Document Type: Article

References (45)

1. Pendergast AM. The Abl family kinases: mechanisms of regulation and signaling. Adv Cancer Res 2002;85: 51-100.
2. Clarkson B, Strife A, Wisniewski D, Lambek CL, Liu C. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Leukemia 2003; 17:1211-62.
3. Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 2004;22: 247-306.
4. Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 2004;5:33-44.
5. Sawyers CL, Druker B. Tyrosine kinase inhibitors in chronic myeloid leukemia Cancer J Sci Am 1999;5:63-9.
6. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640-53.
7. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
8. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295:139-45.
9. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor β. N Engl J Med 2002;347:481-7.
10. Demetri G. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development. Hematol Oncol Clin North Am 2002;16: 1115-24.
11. Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell 2002;109:275-82.
12. Nolen B, Taylor S, Ghosh G. Regulation of protein kinases; controlling activity through activation segment conformation. Mol Cell 2004;15:661-75.
13. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000;289: 1938-42.
14. Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and Imatinib (STI-571). Cancer Res 2002;62:4236-43.
15. Nagar B, Hantschel O, Young MA, et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 2003;112:859-71.
16. Mol CD, Dougan DR, Schneider TR, et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 2004;279:31655-63.
17. Schindler T, Sicheri F, Pico A, Gazit A, Levitzki A, Kuriyan J. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol Cell 1999;3:639-48.
18. Xu W, Doshi A, Lei M, Eck MJ, Harrison SC. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 1999;3:629-38.
19. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25.
20. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
21. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A 2005;102:3395-400.
22. Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science 2004;303:1800-5.
23. Liu Y, Bishop A, Witucki L, et al. Structural basis for selective inhibition of Src family kinases by PP1. Chem Biol 1999;6:671-8.
24. Tamborini E, Bonadiman L, Greco A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004;127:294-9.
25. Wardelmann E, Thomas N, Merkelbach-Bruse S, et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 2005;6:249-51.
26. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005;128:270-9.
27. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
28. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10:262-7.
29. Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A 2005;102:11011-6.
30. Seeliger MA, Young M, Henderson MN, et al. High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. Protein Sci 2005;14:3135-9.
31. Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell 1986;47:277-84.
32. Guan KL, Dixon JE. Protein tyrosine phosphatase activity of an essential virulence determinant in Yersinia. Science 1990;249:553-6.
33. Bliska JB, Guan KL, Dixon JE, Falkow S. Tyrosine phosphate hydrolysis of host proteins by an essential Yersinia virulence determinant. Proc Natl Acad Sci U S A 1991;88:1187-91.
34. Barker SC, Kassel DB, Weigl D, Huang X, Luther MA, Knight WB. Characterization of pp60c-src tyrosine kinase activities using a continuous assay: autoactivation of the enzyme is an intermolecular autophosphorylation process. Biochemistry 1995;34: 14843-51.
35. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 1997;276:307-26.
36. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ. Likelihood-enhanced fast translation functions. Acta Cryst 2005;D61:458-64.
37. Collaborative Computational Project N. The CCP4 suite programs for protein crystallography. Acta Cryt 1994;D50:760-3.
38. Brunger AT, Adams PD, Clore GM, et al. Crystallography and NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 1998;54:905-21.
39. Jones TA, Zou JY, Cowan SW, Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr 1991;A47:110-9.
40. Kleywegt GJaJ, TA. Databases in protein crystallography. Acta Cryst 1998;D54:1119-31 (CCP4 Proceedings).
41. Yamaguchi H, Hendrickson WA. Structural basis for activation of the human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 1996; 384:484-9.
42. MacArthur MW, Thornton JW. Influence of proline residues on protein conformation. J Mol Biol 1991; 218:397-412.
43. Nowakowski J, Cronin CN, Mcree DE, et al. Structures of the cancer-related Aurora-A, Fak and Epha2 protein kinases from nanovolume crystallography. Structure (Camb) 2002;10:1659-67.
44. Cheetham GM, Knegtel RM, Coll JT, et al. Crystal structure of aurora-2, an oncogenic serine/threonine kinase. J Biol Chem 2002;277:42419-22.
45. Bayliss R, Sardon T, Vernos I, Conti E. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol Cell 2003;12:851-62.